BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

953 related articles for article (PubMed ID: 26346232)

  • 1. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
    Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
    Pickett CA; Villines TC; Ferguson MA; Hulten EA
    Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses.
    Udell JA; Opotowsky AR; Khairy P; Silversides CK; Gladstone DJ; O'Gara PT; Landzberg MJ
    Can J Cardiol; 2014 Oct; 30(10):1216-24. PubMed ID: 25154803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
    Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
    Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
    Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Di Napoli M; Silvestrini M
    Cerebrovasc Dis; 2018; 45(5-6):193-203. PubMed ID: 29649819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.
    Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent foramen ovale closure or medical therapy for secondary prevention of cryptogenic stroke: An update meta-analysis of randomized controlled trials.
    Ma Y; Li D; Bai F; Qin F; Li J; Li Y; Liu N; Xie H; Zhou S; Liu Q
    Medicine (Baltimore); 2018 Aug; 97(34):e11965. PubMed ID: 30142823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis.
    Shah R; Nayyar M; Jovin IS; Rashid A; Bondy BR; Fan TM; Flaherty MP; Rao SV
    Ann Intern Med; 2018 Mar; 168(5):335-342. PubMed ID: 29310136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent foramen ovale closure versus medical therapy after cryptogenic stroke: An updated meta-analysis of all randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Ahmed S; Hassan M; Bachuwa G
    Cardiol J; 2019; 26(1):47-55. PubMed ID: 29512097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials.
    Wang TKM; Wang MTM; Ruygrok P
    Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
    Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
    Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
    Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
    Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of patent foramen ovale closure versus medical therapy for prevention of recurrent ischemic neurological events: Impact of medication type.
    Pan X; Xu L; Zhou C; Zhang Z; Sun H
    Medicine (Baltimore); 2021 Jun; 100(25):e26473. PubMed ID: 34160457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
    Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
    Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.